| 5 | 1/1 | 返回列表 |
| 查看: 2036 | 回復(fù): 7 | |||
| 【有獎交流】積極回復(fù)本帖子,參與交流,就有機(jī)會分得作者 YT21 的 4 個金幣 ,回帖就立即獲得 1 個金幣,每人有 1 次機(jī)會 | |||
| 當(dāng)前只顯示滿足指定條件的回帖,點擊這里查看本話題的所有回帖 | |||
[交流]
Hackensack Meridian School of Medicine(新澤西州)張毅實驗室招聘三名博士后
|
|||
|
Three postdoctoral positions are available in Dr. Yi Zhang’s lab at Center for Discovery & Innovation, Hackensack Meridian School of Medicine (New Jersey). Dr. Zhang introduced for the first time the concept of alloantigen-sensitized stem cell memory T cells in sustaining alloimmunity. This concept of T cell stemness stimulates cancer immunotherapy field to develop novel strategies for improving the efficacy of cancer therapy. The Zhang lab has also discovered that Ezh2 plays multiple roles in the regulation of T cell stemness and T cell immunity. Currently, the Zhang lab studies epigenetic therapy, focusing on immune regulation and tumor immune-sensitization. Ongoing research projects investigate: 1) the molecular pathways that mediate Ezh2 actions in T cells; 2) epigenetic therapy to sensitize tumor to T cell immunity; and 3) novel genetic and pharmacologic approaches to program T cells for improving the efficacy of cancer immunotherapy. Advanced technologies, including drug-screening, CRISPR-editing and scRNA-sequencing analysis, are leveraged to facilitate these studies. The ideal candidate should have PhD degree or equivalent, with at least one 1st author publication. Background in immunology, cancer biology and molecular genetics is preferred. The candidate should be highly motivated and able to work independently under the PI’s supervision, with strong scientific ethnic. Please submit application electronically with CV, statement of interest and the names/ emails of three referees to: Dr. Yi Zhang (Professor), Email: yi.zhang@temple.edu. Hackensack Meridian School of Medicine(新澤西州)發(fā)現(xiàn)與創(chuàng)新中心的 Yi Zhang 博士實驗室提供三個博士后職位。張博士首次創(chuàng)立了干細(xì)胞樣記憶T細(xì)胞維持同種異體抗原免疫反應(yīng)的概念。這一概念引導(dǎo)了癌癥免疫治療領(lǐng)域開發(fā)提高癌癥治療功效的新策略。張實驗室還發(fā)現(xiàn)Ezh2在調(diào)節(jié)T細(xì)胞干性和T細(xì)胞免疫中發(fā)揮多重作用。 目前,張實驗室研究表觀遺傳療法,重點是免疫調(diào)節(jié)和腫瘤免疫致敏。正在進(jìn)行的項目研究:1) 在 T 細(xì)胞中介導(dǎo) Ezh2 作用的分子途徑; 2) 表觀遺傳療法增強腫瘤對 T 細(xì)胞免疫敏感; 3) 新的遺傳和藥理學(xué)方法編程 T 細(xì)胞以提高癌癥免疫治療的功效。多項先進(jìn)的技術(shù),包括藥物篩選、CRISPR 編輯和 scRNA 測序分析,被用于促進(jìn)這些研究。 理想的候選人應(yīng)具有博士學(xué)位或同等學(xué)歷,至少有一篇第一作者發(fā)表。有免疫學(xué)、癌癥生物學(xué)和分子遺傳學(xué)背景者優(yōu)先。候選人應(yīng)具有高度的積極性,能夠在PI的指導(dǎo)下獨立工作,具有強烈的科學(xué)素養(yǎng)。請將申請電子版連同簡歷、意向書和三位推薦人的姓名/電子郵件提交至:張毅博士,電子郵件:yi.zhang@temple.edu。 張毅教授的個人簡介網(wǎng)址:https://medicine.temple.edu/yi-zhang (今年9月份正式搬去Hackensack Meridian School of Medicine,新實驗室的網(wǎng)頁尚未準(zhǔn)備好) |
» 搶金幣啦!回帖就可以得到:
+2/266
+1/185
+1/87
+1/86
+1/82
+1/78
+1/37
+1/34
+1/12
+1/9
+1/9
+1/8
+1/8
+1/7
+1/6
+1/5
+1/5
+1/5
+1/4
+1/4
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 266求調(diào)劑 +5 | 哇塞王帥 2026-03-03 | 5/250 |
|
|---|---|---|---|---|
|
[論文投稿]
EST拒稿重投
5+3
|
15102603076 2026-03-02 | 3/150 |
|
|
[考研] 化工專碩調(diào)劑 +4 | 利好利好. 2026-03-03 | 7/350 |
|
|
[考研] 085700資環(huán)求調(diào)劑,初始279,六級已過,英語能力強 +3 | 085700資環(huán)調(diào)劑 2026-03-03 | 4/200 |
|
|
[考研] 290求調(diào)劑 +9 | ErMiao1020 2026-03-02 | 9/450 |
|
|
[考研] 289求調(diào)劑 +7 | BrightLL 2026-03-02 | 9/450 |
|
|
[考研] 化工270求調(diào)劑 +10 | 什么名字qwq 2026-03-02 | 10/500 |
|
|
[論文投稿]
通訊作者寫誰,問題是你意想不到的問題
15+3
|
阿爾法啊 2026-03-01 | 3/150 |
|
|
[考研] 298求調(diào)劑 +7 | axyz3 2026-02-28 | 8/400 |
|
|
[考研] 289求調(diào)劑 +8 | yang婷 2026-03-02 | 9/450 |
|
|
[考研] 一志愿中石油(華東)本科齊魯工業(yè)大學(xué) +3 | 石能偉 2026-03-02 | 3/150 |
|
|
[考研] 材料調(diào)劑 +3 | 恒順自然 2026-03-02 | 3/150 |
|
|
[考研] 291 求調(diào)劑 +3 | 化工2026屆畢業(yè)?/a> 2026-03-02 | 3/150 |
|
|
[考研] 哈工大計算機(jī)劉劼團(tuán)隊招生 +4 | hit_aiot 2026-03-01 | 6/300 |
|
|
[考研] 295求調(diào)劑 +8 | 19171856320 2026-02-28 | 8/400 |
|
|
[考研] 284求調(diào)劑 +10 | 天下熯 2026-02-28 | 11/550 |
|
|
[考研] 291分工科求調(diào)劑 +9 | science餓餓 2026-03-01 | 10/500 |
|
|
[考研] 調(diào)劑 +3 | 簡木ChuFront 2026-02-28 | 3/150 |
|
|
[考研] 311求調(diào)劑 +9 | 南迦720 2026-02-28 | 10/500 |
|
|
[考研] 304求調(diào)劑 +3 | 52hz~~ 2026-02-28 | 5/250 |
|